Escugen has conducted numerous in vitro and in vivo studies using the EZWi-Fit? - based ADCs targeting multiple targets. The results preclinically validated the superior efficacy of EZWi-Fit? platform.
Systematically studies elucidated the mechanism of actions of the EZWi-Fit® at the molecular, cellular, and in vivo levels, including linker cleavage, anti-multi-drug resistance, payload bystander effect, and in vivo efficacy in low-expressing target tumor models. Study results provide strong and convincing evidences that EZWi-Fit® platform technology has superior competitive advantages than other benchmarking ADC platforms in development
Affluent in vitro and in vivo studies of ADCs targeting multiple targets, developed based on EZWi-Fit® platform, demonstrate great efficacy on different tumor models, including CDXs and PDXs. The GLP-compliant repeated-dosing NHP safety studies of several ADCs proof improved tolerability comparing with other benchmarking ADC platforms
